Financial Trading Blog
Stock of the day 08/05/2015 – GW Pharmaceuticals PLC
The cannabis-based pharma company’s growth on the markets has been robust over the past 15 months, starting 2014 at £1.99 before closing out the year at £3.69. A brief foray to lows to £3.10 in the first week of January didn’t last long, and by the end of April GW Pharmaceuticals was trading at an intraday all-time high of £6.95, before falling off slightly to a current trading price of £6.04. Its American listing has seen similar success, hitting a high of $126.61 at the end of April after opening the year at $68.31.
(Source: IT-Finance.com 07/05/2015)
The company clearly has expansion on the mind with it recently raised $179 million by issuing 1.6 million American Depositary Shares to be listed on the NASDAQ Global Market, where GW Pharmaceuticals is currently trading at $108.55.
(Source: IT-Finance.com 07/05/2015)
Obviously for a pharmaceutical company what it has it its pipeline is of incredible importance to investors. GW has just entered phase 2 of its adult epilepsy drug cannabidivarin (which GW has the patent for in Britain with a notice for a US patent attached to the portfolio), whilst its child epilepsy studies for its drug Epodiolex have entered phase 3. It has also recently received Orphan Drug Status (a drug developed for a rare medical condition) for the use of cannabidiol on Dravet Syndrome in new-born babies. These positive developments have helped push GW Pharmaceuticals to its recent all-time highs with investors buoyed by the company’s outlook.
Results back in December saw a full year pre-tax loss of $31.7 million with an $18.7 million rise in revenue to $48.7 million countered by expanding R&D costs, which grew from $43.5 million to $79.5 million, so investors will be looking for an improvement on these figures. Analysts appear just as bullish on the stock as investors, giving GW Pharmaceutical a consensus rating of ‘buy’ and an average target price for its US listing of $117.86.
It's easy to open an account
- Fill in our simple online application form
- Fund your account
- Start trading the global markets instantly!
SEARCH FOR AN ARTICLE:
Enter a keyword and search for all relevant articlesMARKET ANALYSIS
RECENT POSTS
DISCLAIMER
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 64% of retail investors lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. For professional clients, spread betting and CFD trading can also result in losses larger than your initial stake or deposit.
Spreadex Ltd is authorised and regulated by the Financial Conduct Authority, provides an execution only service and does not provide advice in any way. Nothing within this update should be deemed to constitute the provision of investment advice, recommendations, any other professional advice in any way, or a record of our trading prices. This update does not constitute or form part of an offer of, or solicitation for a transaction in any financial instrument, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefore. Any persons placing trades based on their interpretation of the comments or information within this update does so entirely at their own risk.
No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained within this update by Spreadex Ltd or any of its employees and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained within this update.
The information contained within this update is the intellectual property of Spreadex Ltd and is protected by UK and International copyright laws. All rights reserved. Users may however freely download, distribute and reproduce extracts of the contents, subject always to accrediting Spreadex Ltd as the source and providing a hyperlink to www.spreadex.com.
